SalykaSengsayadethMD

Hematologic Oncology

Associate Professor of Medicine, Vanderbilt Univ Sch of Med

Dr. Sengsayadeth is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3601 21st Ave S
Nashville, TN 37232
Phone+1 615-322-3000

Fax+1 615-343-7602

Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Vanderbilt University Medical CenterResidency, Internal Medicine, 2006 - 2009
East Tennessee State University James H. Quillen College of MedicineClass of 2006

PubMed

No Role for Tandem Autologous Stem Cell Transplantation in Modern Treatment Paradigms for Transplant Eligible Multiple Myeloma.
Muhamed Baljevic, Eden Ayele Biltibo, Bhagirathbhai Dholaria, Salyka Sengsayadeth
Transplantation and Cellular Therapy. 2024-09-01
Efficacy and safety of outpatient fludarabine, cyclophosphamide, and rituximab based allogeneic hematopoietic cell transplantation in adults with severe aplastic anemia.
Rachel M Gilmore, Karin Abernathy, Kendall Shultes, Dwight D Eplin, Lindsay Orton
Bone Marrow Transplantation. 2024-09-01
GVHD like skin eruption post-autologous stem cell transplantation.
Johnathan Fraebel, Silvia Park, Rahul Shah, Carlos Prieto-Granada, Emily F Mason
Bone Marrow Transplantation. 2024-06-01

Abstracts/Posters

Venetoclax-Based Salvage Therapy for Post-Hematopoietic Cell Transplantation Relapse in Acute Myeloid Leukemia
Salyka M. Sengsayadeth, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Three-Drug Regimen Improves Protection Against GVHD After Stem Cell TransplantJuly 18th, 2023